_asco-2021-latest-on-parpi-and-other-treatments-for-mcrpc.jpg "ASCO 2021: Latest on PARPi and other treatments for mCRPC from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 10 min 64 sec
✓ Published: 25-May-2021
✓ Published: 25-May-2021
Description:
Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA) and Prof Oliver Sartor (Tulane Cancer Center, New Orleans, USA) discuss the latest on PARPi and other treatments for mCRPC from ASCO 2021. nnDr Shore begins the conversation by introducing himself and Prof Sartor and then they talk about the role of PARP inhibitors for mCRPC. They talk about the efficacy of olaparib, cabazitaxel and talazoparib. nThey then mention a study dealing with differential responses to taxanes and PARP
Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA) and Prof Oliver Sartor (Tulane Cancer Center, New Orleans, USA) discuss the latest on PARPi and other treatments for mCRPC from ASCO 2021. nnDr Shore begins the conversation by introducing himself and Prof Sartor and then they talk about the role of PARP inhibitors for mCRPC. They talk about the efficacy of olaparib, cabazitaxel and talazoparib. nThey then mention a study dealing with differential responses to taxanes and PARP
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_13-14-parp-fox-reads.webp "This video is about 13_14 PARP Fox reads")
_asco-2018-integrating-genomic-data-throughout-treatment-for-prostate-cancer.webp "Prof Kurt Miller (Benjamin Franklin Medical Centre, Berlin, Germany) and Prof Bertrand Tombal (Cliniques Universitaire Saint Luc, Belgium) share their thoughts on the genomic data and its implications for prostate cancer treatment presented from day 1 at ASCO. They emphasise that taking a detailed family history of any breast cancer, ovarian cancer as well as prostate cancers is a vital first step for new patients. nnGenetic counselling for ‘healthy’ family members needs to be considered alo")
⏲ 10 min 0 sec ✓ 03-Jun-2018
_which-different-parp-inhibitors-are-available.webp "This series of animations investigates the current role of PARP inhibitor use in prostate cancer, and what we might expect in the future and has been developed by Prof Phillip Cornford in association with ecancer.nnPARP inhibitors treat certain types of cancer by blocking the PARP enzymes in cells. These enzymes help repair DNA damage, so blocking them can prevent cancer cells from repairing.nnPARP inhibitors have so far demonstrated efficacy in ovarian, breast, pancreatic, peritoneal and metast")
_solo-1-olaparib-or-placebo-for-patients-with-newly-diagnosed-brca-mutated-advanced-ovarian-cancer.webp "Dr. Susana Banerjee spoke to ecancer about the findings of the SOLO1 trial presented at ESMO 2020.nnShe first talked about the rationale behind using a PARP inhibitor (olaparib), for maintenance treatment of patients with newly diagnosed ovarian cancer and BRCA mutation.nnDr Banerjee then went on to explain how the results of the treatment group were better than the placebo group and how the findings of this study can impact the current ovarian cancer treatment.nnSign up to ecancer for free to r")
⏲ 2 min 4 sec ✓ 20-Sep-2020
_embraca-results-of-talazoparib-vs-chemotherapy-relative-to-prior-ct-in-patients-with-advanced-breast-cancer.webp "Dr Johannes Ettl speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the EMBRACA trial.nnHe explains that the trial looked at outcomes of the PARP inhibitor talazoparib versus chemotherapy to treat patients with advanced breast cancer and a germline BRCA mutation who had received chemotherapy prior to taking part in the trial. nnDr Ettl reports that they found there was a benefit to using talazoparib in terms of reponse rate, duration of response, prog")
⏲ 1 min 66 sec ✓ 03-Jun-2019
_part-1-when-to-test.webp "This series of animations investigates the use of PARP inhibitors for prostate cancer treatment and has been developed by Prof Phillip Cornford in association with ecancer.nnBoth EAU and NCCN guidelines suggest germline testing in men with metastatic prostate cancer.nnThey also suggest considering testing in men under 60 years old with multiple family members diagnosed with prostate cancer.nnThis video gives guidelines on when someone should be tested for prostate cancer and what options are ava")
_part-2-dna-damage-response.webp "Short chapter from the Mechanism of Action of PARP inhibitors video focusing on DNA Damage Response (DDR)")
_13-14-parp-fox-reads.jpg)
_asco-2018-integrating-genomic-data-throughout-treatment-for-prostate-cancer.jpg)
_which-different-parp-inhibitors-are-available.jpg)
_solo-1-olaparib-or-placebo-for-patients-with-newly-diagnosed-brca-mutated-advanced-ovarian-cancer.jpg)
_embraca-results-of-talazoparib-vs-chemotherapy-relative-to-prior-ct-in-patients-with-advanced-breast-cancer.jpg)
_part-1-when-to-test.jpg)
_part-2-dna-damage-response.jpg)
![[+]](/images/menu.gif){kind=small}